Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 19, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Biodesix, Inc.
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Subject must be 18 years of age or older at time of signing informed consent form (ICF). 2. A diagnosis of NSCLC. 3. Subject is willing to provide serum samples for VeriStrat testing. 4. EGFR mutation status wild-type (negative) or a tested unknown. 5. For subjects with untested/unknown EGFR status only: The subject must be willing to provide blood samples for GeneStrat testing. 6. Subject is willing to provide serum samples for research, understanding that no test results will be made available either to the subject or the treating physician. 7. Subject is able to read and understand the ICF and agrees to comply with study procedures and requirements.
1\. Subject's ability to understand the requirements of the protocol or to provide informed consent is impaired or subject is unwilling to comply with the protocol requirements.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Oncology Specialties, PC; Clearview Cancer InstituteHuntsville, Alabama
- Lewis & Faye Manderson Cancer Center at DCH Regional Medical CenterTuscaloosa, Alabama
- Highlands Oncology GroupFayetteville, Arkansas
- St. Bernards Cancer Center Hematology / OncologyJonesboro, Arkansas
- Valley Medical Oncology ConsultantsPleasanton, California
- Eastern Connecticut Hematology and Oncology AssociatesNorwich, Connecticut
- Boca Raton Regional Hospital -Lynn Cancer InstituteBoca Raton, Florida
- Lake City Cancer Care, LLCLake City, Florida
- South Eastern Regional Medical CenterNewnan, Georgia
- Summit Cancer CareSavannah, Georgia
- South Georgia Medical CenterValdosta, Georgia
- Edward-Elmhurst HealthcareNaperville, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 19, 2025. Always confirm current availability with the study team.